QIF-T0136

low

Transcranial photobiomodulation (670/808nm)

Tier 2 — Validated (Independently Replicated)

Legacy status: CONFIRMED

Technique Details

Tactic: QIF-E.RD
Status: CONFIRMED
Bands: I0, N1

✚ Therapeutic Application

Propagating NIR photons (670/808nm) absorbed by mitochondrial cytochrome c oxidase (CCO) in dopaminergic neurons. CCO activation increases ATP production, upregulates tyrosine hydroxylase (TH) and VMAT2 expression over days-weeks. Neuroprotective, not acutely stimulatory. Requires cofactor readiness (Fe2+, BH4, B6).

Clinical Analog

Transcranial photobiomodulation for Parkinson's disease neuroprotection

Treats

Parkinson's disease
neurodegeneration
traumatic brain injury

Neural Impact

2 of 7 neural bands affected

I0 N1

Drag to rotate. Click a region to learn more.

Click or hover over a glowing region to see the attack techniques targeting it and their severity.

Scoring

NISS v1.1

0.0None

Validation Status

Theoretical / Not yet validated. This technique has not been independently tested. See the validation dashboard for what has been tested.

Qinnovate Neural Security Atlas Edit this on GitHub